Comparing the use and interpretation of PGMI scoring to assess the technical quality of screening mammograms in the UK and Norway

Radiography ◽  
2015 ◽  
Vol 21 (4) ◽  
pp. 342-347 ◽  
Author(s):  
M. Boyce ◽  
R. Gullien ◽  
D. Parashar ◽  
K. Taylor
1997 ◽  
Vol 3 (4) ◽  
pp. 209-214 ◽  
Author(s):  
R. Wootton ◽  
J. Dornan ◽  
N. M. Fisk ◽  
A. Harper ◽  
C. Barry-Kinsella ◽  
...  

Six subspecialists with considerable experience in fetal ultrasound viewed a selection of pre-recorded ultrasound scans. Scans from 18 patients recorded on VHS video-tape were supplied from five centres in the UK and Ireland, each made on a high-resolution ultrasound machine by an experienced sonologist at a referral centre. Each observer viewed the scans on a large display monitor in an individual viewing booth. The scans were viewed in random order, at randomly selected bandwidths. Observers, who were blinded to both recording and bandwidth, assessed the technical quality on a five-point Likert scale. They also recorded their diagnosis. The six observers each carried out 32 viewing sessions, which gave a total of 192 viewings. There was no significant difference in the perceived technical quality of the scans between the two bandwidths used P 0.09 . Of the 84 recordings transmitted at 1920 kbit s, 71 85 were diagnosed correctly or half correctly' and 13 15 were misdiagnosed. Of the 95 recordings transmitted at 384 kbit s, 66 69 were diagnosed correctly or half correctly' and 29 31 were misdiagnosed. This difference was significant P 0.03. The results indicate that although there were no perceived differences in technical quality between recordings transmitted at 384 or 1920 kbit s, diagnostic accuracy was marginally worse at the lower bandwidth. This suggests that the higher bandwidth conveys more detail and information to the observer, which in turn enables more accurate diagnosis. However, further work is required before a definitive choice can be made about the optimum transmission bandwidth for remote fetal ultrasound studies.


2014 ◽  
Vol 16 (S1) ◽  
Author(s):  
A Steele ◽  
J Morris ◽  
A Jain ◽  
S Iram ◽  
V Reece ◽  
...  

2016 ◽  
Vol 22 (5) ◽  
pp. 309-317 ◽  
Author(s):  
Kamal Gholipour ◽  
Jafar Tabrizi ◽  
Mohammad asghari-Jafarabadi ◽  
Shabnam Iezadi ◽  
Nasrin Farshbaf ◽  
...  

2021 ◽  
pp. flgastro-2020-101713
Author(s):  
Mathuri Sivakumar ◽  
Akash Gandhi ◽  
Eathar Shakweh ◽  
Yu Meng Li ◽  
Niloufar Safinia ◽  
...  

ObjectivePrimary biliary cholangitis (PBC) is a progressive, autoimmune, cholestatic liver disease affecting approximately 15 000 individuals in the UK. Updated guidelines for the management of PBC were published by The European Association for the Study of the Liver (EASL) in 2017. We report on the first national, pilot audit that assesses the quality of care and adherence to guidelines.DesignData were collected from 11 National Health Service hospitals in England, Wales and Scotland between 2017 and 2020. Data on patient demographics, ursodeoxycholic acid (UDCA) dosing and key guideline recommendations were captured from medical records. Results from each hospital were evaluated for target achievement and underwent χ2 analysis for variation in performance between trusts.Results790 patients’ medical records were reviewed. The data demonstrated that the majority of hospitals did not meet all of the recommended EASL standards. Standards with the lowest likelihood of being met were identified as optimal UDCA dosing, assessment of bone density and assessment of clinical symptoms (pruritus and fatigue). Significant variations in meeting these three standards were observed across UK, in addition to assessment of biochemical response to UDCA (all p<0.0001) and assessment of transplant eligibility in high-risk patients (p=0.0297).ConclusionOur findings identify a broad-based deficiency in ‘real-world’ PBC care, suggesting the need for an intervention to improve guideline adherence, ultimately improving patient outcomes. We developed the PBC Review tool and recommend its incorporation into clinical practice. As the first audit of its kind, it will be used to inform a future wide-scale reaudit.


2020 ◽  
Vol 4 (S1) ◽  
Author(s):  
Nathalie Liew ◽  
Zoya Rashid ◽  
Robert Tulloh

Abstract Background Pulmonary hypertension (PH) is commonly seen in adults who have congenital heart disease (CHD). Therapy is available for pulmonary arterial hypertension (PAH) and has greatly benefitted many patients with PAH related to CHD (PAH-CHD) over the last 15 years, with evidence of improved quality of life and prognosis in those with Eisenmenger syndrome and repaired PAH-CHD. In this review, we describe the standard management and advanced therapies for PAH, which are available in specialist PH centres around the UK and Ireland, and how these are used in PAH-CHD. Decisions around the choice of therapy are governed by commissioning and available evidence. Conclusion We explain the different pathways for action and the variety of medications now at our disposal to help this important group of patients.


Sign in / Sign up

Export Citation Format

Share Document